

# QIAGEN NV

ISIN: NL0015001WM6

WKN: N72482149

Asset Class: **Stock**

## Company

2024/05/06 19:23:39



Price

**42.68**

USD

Difference

**-0.71% (-0.31)**



## Contact Details

QIAGEN NV Tel: +31-77-355-66-00

-- Fax: +

Hulsterweg 82 Web: <http://www.qiagen.com>

5912 PL Venlo E-mail: [qiagen@qiagen.com](mailto:qiagen@qiagen.com)

## Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	2,147,560,000		2,393,952,000		2,109,602,000	
<b>Common stock capital</b>		2,702,000		2,702,000		2,702,000
<b>Fixed assets</b>	3,967,630,000		3,893,783,000		4,037,352,000	
<b>Equity capital of a company</b>		3,807,764,000		3,466,611,000		3,096,550,000
<b>Cash and cash equivalents</b>	668,084,000		730,669,000		880,516,000	
<b>Accrued liabilities</b>		12,100,000		11,900,000		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		1,079,293,000		974,523,000		1,517,470,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		1,228,133,000		1,846,601,000		1,532,934,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		202,346,000		273,897,000		324,665,000
<b>Total assets</b>	6,115,190,000	6,115,190,000	6,287,735,000	6,287,735,000	6,146,954,000	6,146,954,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	5,967	6,178	6,028
<b>Equity ratio</b>	62.27%	55.13%	50.38%
<b>Debt-equity ratio</b>	60.60%	81.38%	98.51%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	20.59%	17.44%	18.09%

**Income statement**

	2023	2022	2021
<b>Turnover</b>	1,965,311,000	2,141,518,000	2,251,657,000
<b>Net income</b>	341,303,000	423,211,000	512,599,000
<b>EBIT</b>	376,739,564	501,603,332	625,143,660
<b>Operating income before taxes</b>	429,809,000	512,601,000	625,833,000
<b>Cash Flow</b>	459,455,000	715,264,000	639,001,000
<b>Net interest income</b>	25,582,000	-25,600,000	-44,922,000
<b>Research and development expenses</b>	198,511,000	189,859,000	189,964,000
<b>Income taxes</b>	88,506,000	89,390,000	113,234,000
<b>Result from investments in subsidiaries, associates and other</b>	-	-	-
<b>Revenues per employee</b>	306,967	323,065	348,133

**Board of Directors**

Lawrence Rosen	Chairman of Supervisory Board
Elaine Mardis	Member of Supervisory Board
Eva Pisa	Member of Supervisory Board
Metin Colpan	Member of Supervisory Board
Ross Levine	Member of Supervisory Board
Toralf Haag	Member of Supervisory Board
Bert van Meurs	Member of Supervisory Board
Elizabeth Tallett	Member of Supervisory Board
Eva van Pelt	Member of Supervisory Board
Stephen Rusckowski	Member of Supervisory Board

**Members of Management Board**

Thierry Bernard	Chairman of Managing Board
Jonathan Sheldon	Member of Executive Committee
Philipp von Hugo	Member of Executive Committee
Thomas Schweins	Member of Executive Committee
Ulrich Schriek	Member of Executive Committee
Antonio Santos	Member of Executive Committee
Jean-Pascal Viola	Member of Executive Committee
John Gilardi	Member of Executive Committee
Lezette Young	Member of Executive Committee
Nedal Safwat	Member of Executive Committee
Roland Sackers	Member of Executive Committee
Stephany Foster	Member of Executive Committee